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Introduction 19
Obesity rates have risen markedly in the last 30 years. More than 700 million 20 people worldwide are clinically obese 1,2 . Obesity promotes type 2 diabetes, fatty liver 21 disease, and cardiovascular disease, and is linked with certain cancers [3] [4] [5] . Health care 22 costs associated with obesity and its comorbidities are enormous and will continue to 23 rise as currents trends continue and the population ages 6 . Thus, a further understanding 24 of obesity and its underlying mechanisms and causes are urgently needed. 25
Obesity results from a positive energy balance when more calories are 26 consumed than are used. The surplus energy is packaged into lipid-based storage 27 molecules and sent to fat storage cells called adipocytes. In obesity, there is both an 28 increase in adipocyte size and an increase in adipocyte number to accommodate the 29 lipid 7 . Adipocytes are formed during the process of adipogenesis and arise from stem 30 cells, fibroblasts, or other progenitor cells when appropriately programmed 8 . 31
Adipogenesis is a highly regulated process that requires the activation of several key 32 signaling pathways, including STAT5 and Fyn and activation of the transcription factors 33
PPARγ and C/EBPα. Numerous genes involved in fatty acid transport and storage, such 34 as fatty acid binding protein 4 (Fabp4) are induced during adipogenesis to promote lipid 35 accumulation in adipocytes. 36
Several proteins including Pref-1, Wnt, TGFβ, and Thy1 (formally called CD90) 37
have been shown to inhibit adipogenesis by blocking pro-adipogenic signaling [9] [10] [11] [12] [13] . Our 38 recent study showed that Thy1 blocked the activity of the Src family kinase, Fyn, in pre-39 adipocytes 14 . Thy1 mediated inhibition of Fyn activity prevented adipocyte formation. 40
Interestingly, while pre-adipocytes expressed high levels of Thy1, its expression was 41 lost during adipogenesis, and mature adipocytes expressed almost no Thy1. Thy1 is a 42 member of the immunoglobulin supergene family and is a glycophosphatidyl inositol 43 linked surface protein. While Thy1 is expressed on pre-adipocytes and subsets of 44 fibroblasts, neurons, and stem cells, little is known about how its expression is 45 controlled. We recently showed that Thy1 levels can be regulated by microRNAs. 46 7 ( Fig 2B,D) . Inhibiting global methylation blunts adipogenesis, which is reflected by the 116 decreased levels of Fabp4 expression and in part sustains Thy1 levels. 117 118 5-aza-dC partially restores Thy1 cell surface expression in 3T3-L1 cells when exposed 119 to adipogenic cocktail 120
We next examined Thy1 cell surface expression on 3T3-L1 cells, since Thy1 is a 121 known cell marker on pre-adipocytes and is readily detected via flow cytometry and 122 immunofluorescence. Cells were treated for 7 days daily with either DMSO or 5-aza-dC, 123
while ACT samples were given the adipogenic cocktail starting at day 3, as previously 124 described. The representative histogram in Figure 3A shows cells treated with ACT shift 125 out of the Thy1+ gate into Thy1-during differentiation, while cells treated with ACT and 126 5-aza-dC mostly remain in the Thy1+ gate. As expected, pre-adipocytes treated with 127
ACT expressed significantly less surface Thy1 than cells with media alone, as 128 evidenced by a lower mean fluorescence intensity (MFI) ( Fig 3B) . However, pre-129 adipocytes cultured with ACT and 5-aza-dC showed a significant increase in Thy1 MFI 130 compared to ACT alone, which occurred in tandem with an increase in the percentage 131 8 transcriptional activation of the Thy1 gene involves both the promoter and intron 1 in 139 some cell types 21, 23 , and previous publications have referred to intron 1 as part of the 140 promoter 17,19-23 , we focused on a CpG rich region within intron 1 that we termed Thy1-141 CGI1 (Fig 4A) . Using a pyrosequencer, we analyzed methylation levels of 5 consecutive 142
CpG sites within Thy1-CGI1. 3T3-L1 pre-adipocytes were treated as described 143
previously. We found that Thy1-CGI1 is hypermethylated during differentiation 144 comparing the average DNA methylation of ACT-treated samples to those treated with 145 media alone. Treatment with 5-aza-dC resulted in reduced methylation of these CpG 146 sites in the Thy1 gene in both media alone and ACT-treated samples (Fig. 4B) . 147
Furthermore, individual CpG positions within Thy1-CGI1 showed an increase in DNA 148 methylation when treated with the adipogenic cocktail versus media alone, with a 149 significant increase at CpG position 2 ( Fig 4C) . Methylation decreased across all 5 CpG 150 sites when treated with 5-aza-dC, whether the cells were treated with media alone or 151 with ACT ( Fig 4D-E) . Four of the five CpG sites examined had significantly reduced 152 methylation levels when cells were treated with ACT and 5-aza-dC. Our data indicates 153 that this region is methylation sensitive and can influence Thy1 expression during 154
adipogenesis. 155
To test the methylation status of Thy1 over time during adipocyte differentiation, 156 we examined methylation levels at these five sites at days 0 (prior to ACT), 2, 4, and 6. 9 occurring on day 6 ( Fig 5A) . Day 0 samples showed lower methylation levels compared 162 to other time points in which cells had been exposed to ACT. Furthermore, there were 163 no significant changes at any of the 5 CpG sites when given a single dose of 5-aza-dC 164 ( Fig. 5B ). However, day 6 samples showed a significant two-fold increase in methylation 165 compared to day 0, along with a significant decrease in methylation when cells were 166 exposed daily to 5-aza-dC at all five CpG sites (Fig. 5C ). This implies that during the 167 normal adipogenic process, CpG sites at the Thy1 locus become hypermethylated, 168 which may blunt Thy1 expression and allow for differentiation to occur. 169 170
Discussion 171
Excessive adipogenesis can lead to weight gain and obesity, which affects over 172 700 million people worldwide. The consequences of obesity can be dire, including the 173 development of cardiovascular or liver disease, diabetes, and other comorbidities, which 174 result in significant morbidity and mortality. Therefore, understanding the adipogenic 175 pathway(s) and molecular changes that foster adipocyte differentiation will elucidate the 176 mechanisms contributing to the pathogenesis of obesity. New understanding should 177 lead to better solutions for this growing problem, as lifestyle changes (e.g. improved diet 178 and exercise) are often insufficient. Although genome-wide studies have shown that 179 changes in histone methylation/acetylation occur during adipogenesis 25, 36, 37 , few 180 specific adipogenesis-relevant genes have been identified as influenced by epigenetic 181 changes (e.g. DNA methylation). In this study, we identify Thy1 as a methylation 182 sensitive gene and demonstrate that DNA methylation plays an active role in 10 adipogenesis. Ultimately, we found that inhibiting DNA methylation blunts adipogenesis 184 and sustains Thy1 at levels that may retard or suppress adipogenesis. 185
Thy1 is a cell surface protein that is expressed on mouse thymocytes and on 186 both mouse and human pre-adipocytes 38, 39 . We have previously shown in mouse 3T3-187 L1 cells that Thy1 is down-regulated in a time dependent manner during adipocyte 188 differentiation, while cells overexpressing Thy1 cells no longer differentiate, even when 189
given an adipogenic cocktail, which typically causes 3T3-L1 cells to differentiate into 190 adipocytes after 6-8 days of exposure. However, here we show that 5-aza-dC blunts 191 adipogenesis, even in the presence of ACT. These findings correlate with reduced 192 levels of Fabp4 expression at both the protein and mRNA levels, along with partially 193 attenuated levels of Thy1 when exposed to a global methylation inhibitor. Fabp4 levels 194 inversely correlate with Thy1 levels; Fabp4 expression increases while Thy1 is 195 suppressed during adipogenesis 14 . Therefore, blunted levels of Fabp4 are likely another 196 contributing factor that impedes adipogenesis. We also demonstrated that during 197 adipogenesis, Thy1-CGI1 methylation increases, which likely contributes to reduced 198 Thy1 expression. While we saw significant changes at CpG position 2 in ACT-treated 199 samples relative to untreated (media alone) cells ( Fig. 4C ), we observed similar trends 200 for the other CpG positions. These results are consistent with previous studies showing 201 alterations in methylation status at CpG sites can cause significant changes in gene 202 expression 40, 41 . Treatment with the methylation inhibitor, 5-aza-dC, resulted in 203 hypomethylation of Thy1-CGI1, which in part may contribute to the attenuation of Thy1 204 expression. Since 5-aza-dC is a global DNA methylation inhibitor, it can affect other 205 genes involved in adipogenesis in addition to Thy1. Our data suggest that DNA 206 methylation is a necessary regulatory mechanism for pre-adipocytes to differentiate into 207 fat cells, consistent with recent reports implying DNA methylation is involved in lineage-208 specific adipocyte development 24,42 . 209 Adipogenesis is a complex process that is controlled by many factors, which 210 include epigenetic and post-transcriptional modifications. Previous studies have 211 established that the expression/activity of microRNAs, small RNAs ~20-22 bp in length 212 that bind to and block the transcription of specific targeted genes, play a role 213 adipogenesis 43 . Furthermore, in obesity, it has been shown that there are significant 214 changes in the expression of microRNAs (miR), such as an increase in miR-103 215 levels 44, 45 . We have recently shown that miR-103 levels increase during adipogenesis 216 and can bind the 3' UTR of Thy1 to blunt its expression 15 . Here, we confirmed that the 217 levels of miR-103 increase during adipogenesis, and that these levels were unchanged 218 by treatment with 5-aza-dC, suggesting that the regulatory effects of Thy1 methylation 219 are separate from changes in microRNA expression ( Figure S3 ). This represents 220 another potential facet of Thy1 regulation. Therefore, several, possibly overlapping 221 mechanisms are involved in the adipogenic pathway. This has important implications for 222 developing therapeutic interventions to combat adipogenesis and obesity; more than 223 one aspect of this regulatory mechanism may need to be targeted to cause a significant 224 effect. 225 Wnt10a is known to be upregulated and essential for bone formation [48] [49] [50] 231 Thy1 also plays a critical role 51, 52 . It was recently shown that Thy1 is upregulated during 232 osteoblastogenesis and that Thy1cells (knockdown and knockout) cannot differentiate 233 into osteoblasts 53 . However, changes in Thy1 DNA methylation during osteoblast 234 formation have not been analyzed. In our present study, we show that Thy1 levels are 235 sustained, while FABP4 levels are lowered in mMSCs treated with 5-aza-dC in the 236 presence of ACT. While many epigenetic factors aid in stem cell maintenance, 54 237 changes in the methylation status of genes, such as Thy1, may alter stem cell state. 238
Since Thy1 is highly expressed in MSCs and pre-adipocytes, maintaining Thy1 239 expression may be the key to remaining a precursor cell. However, further investigation 240 is needed. While we saw an increase in Thy1 methylation in mouse pre-adipocyte cells, 241 a crucial next step would be to determine basal Thy1 expression levels and the 242 methylation status of MSCs derived from adipose tissues of obese and non-obese 243 individuals. Testing the ability of these cells to differentiate into fat cells may correlate 244 with their Thy1 expression profiles. Such investigations are likely to provide additional 245 evidence of Thy1's critical role in adipogenesis and would further underline the 246 importance of our findings. 247
While we show that 5-aza-dC treatment decreased methylation in the Thy1-CGI1 248 region and blunted adipogenesis, it is possible that hypomethylating the Thy1 gene at 249 the same time could affect other cell types, such as, fibroblasts (involved in fibrosis); it 250 has been established that Thy1 expression is up-regulated during and involved in 251 myofibroblast differentiation 55 . Future studies could examine other CpG islands in the 252 13 traditional promoter region and downstream regions to investigate whether methylation 253 of these sites is also essential for Thy1's involvement in adipogenesis, fibrosis, and 254 other functions. While the Thy1 gene may be a key target for methylation during 255 adipogenesis, there are undoubtedly other genes regulated by methylation during 256 differentiation. Further investigation is necessary to identify other essential genes, which 257 is fundamental to understanding the adipogenic pathway. 258
In summary, our work shows for the first time that Thy1 has increased DNA 259 methylation during adipogenesis. We demonstrate herein that inhibiting DNA 260 methylation attenuates the loss of Thy1 when cells are stimulated to differentiate into 261 adipocytes. Blocking methylation leads to sustained Thy1 expression and prevents 262 adipogenesis. These studies further highlight the role of genomic methylation and 263
Thy1's involvement in adipogenesis, which suggests these pathways may be 264 dysregulated in metabolic diseases in which adipogenesis is elevated, such as obesity. All cells were incubated at 37°C with 7% humidified CO 2 . 3T3-L1 cells were maintained 274 in 10% calf serum supplemented with DMEM media. C57BL/6 Mouse Bone Marrow 275
Western blot analysis 299
Cells were lysed with 60 mM Tris, 2% SDS, and protease inhibitor cocktail (Sigma-300 Aldrich). Ten μ g of protein was loaded per lane and run on SDS-PAGE gels. Protein 301 gels were transferred to 0.45 um Immobilon-PVDF membranes (Millipore, Temecula, 302 CA) and blocked with 5% BSA in 0.1% Tween 20 in PBS. Primary antibodies, sheep 303 anti-mouse Thy1 (R&D), rabbit anti-mouse Fabp4 (Cell Signaling), and rabbit anti-304 mouse β -tubulin (Cell Signaling) were diluted 1:5000, 1:500, and 1:5000, respectively, 305 and incubated for 1 h. Membranes were washed in 0.1% Tween 20 in PBS then 306 incubated in anti-sheep or anti-rabbit HRP-conjugated secondary antibodies at 1:5000 307 or 1:20,000 dilution, respectively. Protein was visualized using Immobilon Western 308 chemiluminescent horseradish peroxidase substrate (Millipore). MagicMark XP protein 309 standard protocol used for ladder (Novex). Blots were developed by X-ray film. All blots 310 are provided as uncropped images in the supplementary data. 311 312
Flow cytometry 313
Cells were trypsinized and washed in PBS, then fixed with 2% PFA and blocked with 314 1:50 human Fc receptor blocker (Miltenyi Biotech Inc., San Diego, CA) in PBS. The 315 cells were then incubated with anti-mouse Thy1.2-PE conjugated antibody, 1:500, (BD 316
Biosciences, San Jose, CA) for 1 h on ice. Cells were washed and resuspended in PBS. 317
Cells were analyzed on a LSR II flow cytometer running FACSDIVA software (BD 318 Biosciences). Analysis of fluorescence data was performed using FlowJo software 319 v10.1 (FlowJo, LLC, Ashland, Oregon). 320
321

Immunofluorescent staining 322
Cells treated in 12-well plates were washed with 1X PBS and fixed with 2% PFA for 10 323 min and washed three times with PBS. Cells were blocked in 1% BSA and 0.1% Triton 324 X-100 in PBS with normal donkey serum (Jackson Immunoresearch) and Fc-blocker 325 1:50 (BD Biosciences). The primary antibodies used were Thy1.2-PE conjugated 326 antibody, (BD Biosciences, San Jose, CA) and Fabp4 (Cell Signaling), which were 327 diluted 1:500 in 1% BSA and incubated for 2 h at room temperature in the dark. After 328 removal of primary antibody and three washes, secondary antibody (donkey anti-rabbit 329 AF647) was applied at a 1:2000 dilution for an hour. Cells were then washed and 330 visualized on an EVOS-FL Cell Imaging System (Thermo Fisher). 331
332
DNA extraction and Bisulfite conversion 333
Genomic DNA was isolated from cells using a DNeasy DNA extraction kit (Qiagen, 334
Valencia, CA) and quantified using the NanoDrop 1000 spectrophotometer ( Methylation levels were measured in the first CpG island of intron 1, which is part of the 356 promoter 17,20-23 of mouse Thy1 (chr9:44,043,384-44,048,579; GRCm38/mm10) (94bp-357 349bp) using the pyrosequencing assay. Gene-specific primers for Thy1 were designed 358 using the Pyro-Mark assay design software, version 2.0 (Qiagen, Valencia, CA). The 359 program automatically generated primer sets that included both PCR and sequencing 360 primers, based on selected target sequences. One of the primers was biotinylated to 361 enable immobilization to streptavidin-coated beads. The sequences were as follows: 362 showing treatment with 5-aza-dC resulted in an increase in Thy1 total protein levels in 541 both media alone and adipogenic cocktail exposed samples. ACT samples also had a 542 decrease in Fabp4 protein levels when treated with 5-aza-dC, shown by a 543 26 representative western blot. C-D) RT-qPCR shows treatment with 5-aza-dC increases 544 Thy1 mRNA and decreases Fabp4 mRNA levels in ACT samples. Relative percentages 545 were normalized to 100% to media DMSO for Thy1 mRNA or 100% of ACT DMSO for 546 DNA methylation of Thy1-CGI1 showed an increase in methylation in ACT cells 566 compared to media alone, while treatment with the methylation inhibitor, 5-aza-dC 567 resulted in a decrease of overall methylation in both groups. C) Individual CpG position 568 sites were measured across Thy1-CGI1 and showed increases in methylation with ACT 569 
